Clinical outcomes of pediatric macular edema associated with non-infectious uveitis

被引:3
|
作者
Nguyen, Anh Hong [1 ]
Mekonnen, Bethlehem [1 ]
Kim, Eric [2 ]
Acharya, Nisha R. [1 ,2 ,3 ]
机构
[1] Univ Calif San Francisco, Dept Ophthalmol, 490 Illinois St,2nd Floor, San Francisco, CA 94158 USA
[2] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
基金
美国国家卫生研究院;
关键词
Pediatric uveitis; Macular edema; OCT;
D O I
10.1186/s12348-021-00236-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Macular edema (ME) is the most frequent cause of irreversible visual impairment in patients with uveitis. To date, little data exists about the clinical course of ME in pediatric patients. A retrospective, observational study was performed to examine the visual and macular thickness outcomes of ME associated with chronic, noninfectious uveitis in pediatric patients. Methods Pediatric patients with noninfectious uveitis complicated by ME seen in the University of California San Francisco Health System from 2012 to 2018 were identified using ICD-9 and ICD-10 codes. Data were collected from medical records including demographics, diagnoses, ocular history, OCT imaging findings, complications, and treatments at first encounter and at 3, 6, 9, and 12-month follow-up visits. Cox proportional hazards regression was used to investigate the association between different classes of treatment (steroid drops, steroid injections, oral steroids and other immunosuppressive therapies) and resolution of macular edema. Results The cohort comprised of 21 children (26 eyes) with a mean age of 10.5 years (SD 3.3). Undifferentiated uveitis was the most common diagnosis, affecting 19 eyes (73.1%). The majority of observed macular edema was unilateral (16 patients, 76.2%) and 5 patients had bilateral macular edema. The mean duration of follow-up at UCSF was 35.3 months (SD 25.7). By 12 months, 18 eyes (69.2%) had achieved resolution of ME. The median time to resolution was 3 months (IQR 3-6 months). Median best-corrected visual acuity (BCVA) at baseline was 0.54 logMAR (Snellen 20/69, IQR 20/40 to 20/200). Median BCVA at 12 months was 0.1 logMAR (Snellen 20/25, IQR 20/20 to 20/50) Corticosteroid injections were associated with a 4.0-fold higher rate of macular edema resolution (95% CI 1.3-12.2, P = 0.01). Conclusions Although only 15% of the pediatric patients with uveitis in the study cohort had ME, it is clinically important to conduct OCTs to detect ME in this population. Treatment resulted in 69% of eyes achieving resolution of ME by 12 months, accompanied with improvement in visual acuity. Corticosteroid injections were significantly associated with resolution of macular edema.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Non-infectious pediatric uveitis in a single french tertiary center
    Dalila Nouar
    Cyrille Hoarau
    Florence Uettwiller
    Marie-Laure Le Lez
    Pediatric Rheumatology, 12 (Suppl 1)
  • [32] Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis
    Hassan, Muhammad
    Nguyen, Nam V.
    Halim, Muhammad Sohail
    Afridi, Rubbia
    Sadiq, Mohammad Ali
    Karkhur, Samendra
    Vigil, Erin
    Karabekirogullari, Selen
    Quan Dong Nguyen
    Do, Diana V.
    Sepah, Yasir J.
    JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION, 2019, 9 (1)
  • [33] Hypothyroidism and non-infectious uveitis
    Azad, Shorya Vardhan
    Gogia, Varun
    Venkatesh, Pradeep
    Takkar, Brijesh
    EYE, 2018, 32 (11) : 1795 - 1796
  • [34] OUTCOMES OF NON-INFECTIOUS PAEDIATRIC UVEITIS IN THE ERA OF BIOLOGIC THERAPIES
    Cann, Megan
    Rashed, Fatima
    Crawford, Andrew
    Dick, Andrew
    Clark, Sarah
    Ramanan, Athimalaipet V.
    Guly, Catherine
    RHEUMATOLOGY, 2017, 56
  • [35] OUTCOMES OF NON-INFECTIOUS PAEDIATRIC UVEITIS IN THE ERA OF BIOLOGIC THERAPY
    Cann, Megan
    Rashed, Fatima
    Dick, Andrew
    Clark, Sarah
    Ramanan, Athimalaipet
    Guly, Catherine
    RHEUMATOLOGY, 2017, 56 : 39 - 40
  • [36] Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy
    Megan Cann
    Athimalaipet V. Ramanan
    Andrew Crawford
    Andrew D. Dick
    Sarah L. N. Clarke
    Fatima Rashed
    Catherine M. Guly
    Pediatric Rheumatology, 16
  • [37] Treatment of Non-infectious Uveitic Macular Edema with the Intravitreal Dexamethasone Implant
    Nobre-Cardoso, Joao
    Champion, Emmanuelle
    Darugar, Adil
    Fel, Audrey
    Lehoang, Phuc
    Bodaghi, Bahram
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2017, 25 (04) : 447 - 454
  • [38] Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy
    Cann, Megan
    Ramanan, Athimalaipet V.
    Crawford, Andrew
    Dick, Andrew D.
    Clarke, Sarah L. N.
    Rashed, Fatima
    Guly, Catherine M.
    PEDIATRIC RHEUMATOLOGY, 2018, 16
  • [39] Efficacy of High-Dose Methotrexate in Pediatric Non-Infectious Uveitis
    Wieringa, Wietse G.
    Armbrust, Wineke
    Legger, G. Elizabeth
    Los, Leonoor I.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2019, 27 (08) : 1305 - 1313
  • [40] Risk of Elevated Intraocular Pressure (IOP) in Pediatric Non-infectious Uveitis
    Kothari, Srishti
    Pistilli, Maxwell
    Foster, C. Stephen
    Sen, H. Nida
    Suhler, Eric B.
    Thorne, Jennifer E.
    Jabs, Douglas A.
    Nussenblatt, Robert B.
    Rosenbaum, James T.
    Kempen, John H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)